New Crestor data sheds light on CV disease

New data from the AURORA trial, presented at the American College of Cardiology Scientific Sessions, held in Orlando, Florida, and published  in the New England Journal of Medicine, showed that there was no  difference between Anglo-Swedish drug major AstraZeneca's Crestor  (rosuvastatin) 10mg and placebo in reducing the combined endpoint of  cardiovascular death, non-fatal stroke and non-fatal myocardial  infarction in patients with end-stage renal disease undergoing chronic  haemodialysis.

During a median follow-up period of 3.8 years, 396 patients in the  rosuvastatin group and 408 in the placebo arm reached the primary end  point (p=0.59).

"The lack of observed benefit with statin therapy in AURORA suggests  that CV disease in these patients receiving chronic hemodialysis differs  from that in other clinical settings," said Michael Cressman,  AstraZeneca's medical science director for Crestor.